LGND
LIGAND PHARMACEUTICALS INC
+6.35 (+2.31%)281.55USD65.2K成交股數5.6B市值29.2本益比(近四季)19.3股價營收比+33.7%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 63.7M+41% | 51.7M+21% | 115M+123% | 47.6M+15% | 45.3M+46% | 42.8M+30% | 51.8M+97% | 41.5M-6% | 31.0M | 32.9M | 26.4M | 44.0M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 14.7M | 2.1M | 21.0M | 6.6M | 50.1M | 4.4M | 5.7M | 5.4M | 6.0M | 5.5M | 6.9M | 6.7M |
| 銷售管理費用 | 29.1M | 20.8M | 28.4M | 20.2M | 18.8M | 25.6M | 24.5M | 17.6M | 11.0M | 14.7M | 11.3M | 10.9M |
| 營業利益 | 8.6M-124% | 17.4M-280% | 54.9M+1648% | 8.4M-144% | −36.2M-1312% | −9.6M-413% | 3.1M-258% | −19.1M-234% | 3.0M | 3.1M | −2.0M | 14.2M |
| 營業利益率 | 13.5% | 33.6% | 47.6% | 17.7% | -79.9% | -22.5% | 6.1% | -46.0% | 9.6% | 9.4% | -7.5% | 32.3% |
| 稅後淨利 | 48.5M-214% | −13.3M-57% | 117M-1735% | 4.8M-109% | −42.5M-149% | −31.1M+203% | −7.2M-413% | −51.9M-224% | 86.1M | −10.3M | 2.3M | 41.9M |
| 淨利率 | 76.2% | -25.8% | 101.6% | 10.2% | -93.6% | -72.6% | -13.8% | -125.0% | 278.1% | -31.3% | 8.7% | 95.4% |
| 稀釋 EPS | 2.22-200% | -0.67-61% | 5.68-1556% | 0.24-108% | -2.21-147% | -1.70+188% | -0.39-400% | -2.88-224% | 4.75 | -0.59 | 0.13 | 2.33 |
| 稀釋股數 | 21.8M | 19.9M | 20.6M | 19.9M | 19.2M | 18.3M | 18.4M | 18.0M | 18.1M | 17.4M | 17.7M | 18.0M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 1.0B | 115M | 139M | 67.7M | 48.0M | 72.3M | 63.6M | 18.1M | 50.1M | 19.3M | 28.4M | 88.7M |
| 應收帳款 | 67.0M | 53.4M | 57.6M | 41.3M | 38.5M | 38.4M | 34.3M | 37.5M | 28.4M | 36.0M | 28.0M | 29.2M |
| 存貨 | 10.3M | 13.3M | 11.9M | 15.5M | 14.6M | 14.1M | 16.7M | 18.7M | 21.3M | 25.4M | 26.9M | 14.0M |
| 總資產 | 2.2B | 1.5B | 1.5B | 949M | 905M | 942M | 955M | 866M | 914M | 769M | 758M | 811M |
| 有息負債 | 1.1B | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 1.2B | 535M | 527M | 120M | 110M | 111M | 114M | 91.2M | 107M | 101M | 93.2M | 165M |
| 股東權益 | 968M | 997M | 950M | 827M | 796M | 830M | 841M | 775M | 807M | 668M | 665M | 646M |
| 負債比 | 55.7% | 34.9% | 35.7% | 12.7% | 12.1% | 11.8% | 11.9% | 10.5% | 11.7% | 13.2% | 12.3% | 20.3% |
| 淨現金(現金 − 有息負債) | −120M | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 48.7M | – | – | −25.4M-236% | – | – | – | 18.7M | – | – | 33.9M |
| 資本支出 | – | 228K | – | – | 214K | – | – | – | 105K | – | – | 2.4M |
| 自由現金流 | – | 48.5M | – | – | −25.7M-238% | – | – | – | 18.6M | – | – | 31.5M |
| 折舊攤銷 | – | 8.2M | – | – | 8.8M | – | – | – | 8.8M | – | – | 9.5M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 93.7% | – | – | -56.6% | – | – | – | 60.1% | – | – | 71.7% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 268M
| Development And Licensing Of Biopharmaceutical Assets | 268M | 100.0% | +60.4% |
|---|
產品／服務2025 年度 · 1.00
| Royalty 小計 | 161M | 16100100000.0% | +48.0% |
|---|---|---|---|
| Intangible Royalty Assets 小計 | 133M | 13253400000.0% | +39.0% |
| Contract Revenue 小計 | 66.9M | 6687300000.0% | +143.4% |
| Contract Revenue And Income 小計 | 66.9M | 6687300000.0% | +143.4% |
| Income From Divestiture Transactions 小計 | 53.1M | 5307200000.0% | – |
| Material Sales Captisol 小計 | 40.2M | 4021300000.0% | +30.2% |
| Material Sales Captisol Core 小計 | 40.2M | 4021300000.0% | +30.2% |
| Royalty Kyprolis 小計 | 35.5M | 3553400000.0% | -7.4% |
| Filspari 小計 | 32.0M | 3197100000.0% | +162.5% |
| Financial Royalty Assets 小計 | 28.5M | 2846700000.0% | +111.7% |
| QARZIBA 小計 | 23.7M | 2373900000.0% | +113.5% |
| Royalty Rylaze 小計 | 13.4M | 1335000000.0% | -2.9% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 268M | +60.4% | 124M | 46.4% | 6.13 | 48.9M |
| FY2024 | 167M | +27.3% | −4.0M | -2.4% | -0.22 | 95.2M |
| FY2023 | 131M | -33.1% | 52.2M | 39.7% | 2.94 | 46.1M |
| FY2022 | 196M | -18.8% | −33.4M | -17.0% | -1.98 | 120M |
| FY2021 | 242M | +47.7% | 57.1M | 23.7% | 3.31 | 70.0M |
| FY2020 | 164M | +36.0% | −3.0M | -1.8% | -0.18 | 50.1M |
| FY2019 | 120M | -52.2% | 629M | 523.2% | 31.85 | −31.9M |
| FY2018 | 251M | – | 143M | 57.0% | 5.96 | 193M |